

Regd. Office :
1506, Chiranjiv Tower,
43, Nehru Place, New Delhi-110019
CIN No. : L74899DL1993PLC056594

Tel. : 011 - 47589500, 41608929
Tel. : 011 - 21800032
Fax : 011 - 26213081
Web : www.medicamen.com

Ref: STEX/OUTCOME/2018-19

Date: 11th February, 2019

BSE Limited
Department of Corporate Services-Listing
PJ Towers, Dalal Street
Mumbai- 400001

Company No.: 531146

Sub. : Outcome of Board Meeting.

Dear Sir,

We wish to inform you that the Board of Directors of the Company at its meeting held today approved the Un-Audited Financial Results of the Company for the quarter ended on December 31, 2018.

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the following:

- Statement showing the Un-Audited Financial Results of the Company for the quarter ended on December 31, 2018 as **Annexure-A** and
- Limited Review Report on the Un-Audited Financial Results as **Annexure-B**

Further Board of Directors at their meeting approved the following resolutions:

- Appointment of Dr Vimal Kumar Shrawat as an Additional Director (Non-Executive) of the Company.
- Cessation of Mr. Klaus Snej Jensen from the post of Independent Director of the Company.
- Appointment of Ms. Sangeeta Bishnoi as an Additional Director (Independent) of the Company.
- An Investor Release dated 11th February, 2019 on the financial results is enclosed at **Annexure-C**.

The meeting of the Board of Directors commenced on 11:30 am and concluded at 03.15 p.m.

The Un-Audited Financial Results of the Company for the quarter ended December 31, 2018, as approved by the Board, will also be available on the Company's website at www.medicamen.com.

This is for your information and records.

Thanking You.

Yours faithfully,
For Medicamen Biotech Limited


Parul Choudhary
Company Secretary
ACS- 44157





MEDICAMEN BIOTECH LIMITED

Regd. Office: 1506, Chiranjiv Tower, 43, Nehru Place, New Delhi-110019

CIN : L74899DL 1993PLC056594

E-mail : cs@medicamen.com, www.medicamen.com

Un-audited Standalone Financial Results for the Quarter and Nine Months ended on 31st Dec' 2018

PART I		Rupees in Lacs (Except per Share data)				
Particulars	Quarter Ended			9 Months Ended		Year Ended
	3 Months Ended 31.12.2018	3 Months Ended 30.09.2018	3 Months Ended 31.12.2017	9 Months Ended 31.12.2018	9 Months Ended 31.12.2017	31.03.2018
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Income from operations						
(a) Net Sales / Income from operations	2,408.25	3,248.82	2,829.29	8,933.41	8,220.64	11150.72
(b) Other Income	7.12	180.54	(21.55)	303.95	88.96	188.79
(c) Total Revenue	2,415.37	3,429.36	2,807.74	9,237.36	8,309.60	11,339.51
2 Expenses						
a) Cost of Material Consumed	1,629.24	2,049.14	1,763.39	5,612.58	5,013.42	6878.24
b) Purchase of Goods Traded	-	-	(0.00)	-	0.05	0.05
c) Changes in inventory of Finished Goods and Work in Progress	(184.09)	106.68	(158.22)	185.04	(163.14)	(113.07)
d) Employees Benefits Expenses	212.94	236.99	243.70	666.72	718.13	905.30
e) Finance Cost	20.33	35.11	74.35	91.21	189.76	240.81
f) Depreciation and Amortisation Expenses	59.24	48.42	56.32	155.36	155.90	205.79
g) Other expenses	312.12	442.05	487.54	1195.90	1382.58	1832.38
Total Expenses	2,049.78	2,918.39	2,467.09	7,906.81	7,296.71	9,949.51
3 Profit/(Loss) before Exceptional Items & Tax (1 - 2)	365.59	510.97	340.65	1,330.55	1,012.89	1,390.00
4 Exceptional Items (Commercial Tax Expenses Related to Earlier Years)	-	-	-	-	-	-
5 Profit/(Loss) before Extra Ordinary Items & Tax (3 - 4)	365.59	510.97	340.65	1,330.55	1,012.89	1,390.00
6 Tax Expenses						
Current Year	132.83	159.70	74.06	426.24	206.52	401.78
Deferred Tax Liability	(7.69)	(4.71)	(17.40)	(14.32)	(18.66)	(23.05)
Total Tax Expense	125.14	154.99	56.65	411.92	187.85	378.73
7 Net Profit /Loss for the period from Continuing operation (5- 6)	240.45	355.98	284.00	918.63	825.04	1,011.27
8 Other Comprehensive Income						
Item that will not reclassified to Profit & Loss	-	-	-	-	-	-
9 Total Comprehensive Income net of Tax	240.45	355.98	284.00	918.63	825.04	1,011.27
10 Paid up equity share capital (Rs. 10/- per share)	1,170.00	1,170.00	1137.60	1,170.00	1137.60	1170.00
11 Earning Per Share (Rs.)						
Basic	2.06	3.05	2.49	7.85	7.25	9.03
Diluted	2.06	3.05	2.49	7.85	7.25	9.03

NOTES :

- The above results after being reviewed by the Audit Committee have been taken on record by the Board at its Meeting held on 11th Feb, 2019.
- The figures are regrouped in previous year also, wherever considered necessary.
- The company operates only in one business segment , viz. Pharmaceuticals formulations, hence segment reporting is not applicable
- Limited Review Report has been carried out by the Statuary Auditor for the above period.

For & on behalf of Board of Directors
Medicamen Biotech Limited

R. Bishnoi
(Rahul Bishnoi)
Chairman

Place : New Delhi

Dated : 11th Feb'2019

Independent Auditor's Review Report on Standalone Quarterly Financial Results

To


The Board of Directors,
Medicamen Biotech Ltd.
1506, Chiranjiv Tower, 43,
Nehru Place New Delhi-110019

We have reviewed the accompanying statement of unaudited financial results of **Medicamen Biotech Limited** for the quarter ended on 31st December, 2018 being submitted by the Company pursuant to requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rai Qimat & Associates
Chartered Accountants



(Membership Number: 080857)

Place: Gurgaon
Date: 11.02.2019




Medicamen Biotech Limited

Q3 FY19 Presentation
February 2019


Quarter performance

Revenue and margins for the quarter were strained due to a planned shut down of the Bhiwadi plant for facility upgradation



Note: in INR Lakhs

Bhiwadi plant upgradation



Oncology formulation plant at Haridwar (Unit II) underway



- ▶ Dr. V.K. Shrawat has been appointed as Director. His expertise and knowledge of oncology will be an asset and accelerate the execution of plant with highest standards.

Building at site

Reorganization of internal and external plant structure complete as per international drug manufacturing requirements

Machinery

Procurement of manufacturing equipment initiated and carried out in tranches

Drug and composition

New formulations and compositions under development at the R&D center


Detailed Profit and Loss Statement

In INR Lakhs

Particulars	3 months ended 31 Dec 2018 (unaudited)	3 months ended 30 Sep 2018 (unaudited)	3 months ended 31 Dec 2017 (unaudited)	9 months ended 31 Dec 2018 (unaudited)	9 months ended 31 Dec 2017 (unaudited)	Year ended 31 Mar 2018 (audited)
Income from operations						
Net sales/income from operations	2,408.3	3,248.8	2,829.3	8,933.4	8,220.6	11,150.7
Other income	7.1	180.5	-21.5	303.9	89.0	188.8
Total Revenue	2,415.4	3,429.4	2,807.7	9,237.4	8,309.6	11,339.5
Expenses						
Cost of material consumed	1,629.2	2,049.1	1,763.4	5,612.6	5,013.4	6,878.2
Purchase of goods traded	-	-	-0.0	-	0.0	0.0
Changes in inventory of finished goods and WIP	-184.1	106.7	-158.2	185.0	-163.1	-113.1
Employee benefit expenses	212.9	237.0	243.7	666.7	718.1	905.3
Finance Cost	20.3	35.1	74.4	91.2	189.8	240.8
Depreciation and Amortization expenses	59.2	48.4	56.3	155.4	155.9	205.8
Other expenses	312.1	442.1	487.5	1,195.9	1,382.6	1,832.4
Total Expenses	2,049.8	2,918.4	2,467.1	7,906.8	7,296.7	9,949.5
Profit / (Loss) before Exceptional items and tax	365.6	511.0	340.6	1,330.5	1,012.9	1,390.0
Exceptional items (Commercial tax expenses for prior years)	-	-	-	-	-	-
Profit / (Loss) before tax	365.6	511.0	340.6	1,330.5	1,012.9	1,390.0
Tax expenses:						
Current year	132.8	159.7	74.1	426.2	206.5	401.8
Deferred Tax Liability	-7.7	-4.7	-17.4	-14.3	-18.7	-23.1
Net Profit / (Loss) for the period before minority interest	240.4	356.0	284.0	918.6	825.0	1,011.3
Share of profit / (loss) of associates	-	-	-	-	-	-
Minority interest	-	-	-	-	-	-
Net Profit / (Loss) after taxes and minority interest	240.4	356.0	284.0	918.6	825.0	1,011.3
Paid up equity share capital (Rs. 10/- per share)	1,170.0	1,170.0	1,137.6	1,170.0	1,137.6	1,170.0
Earnings per share (Rs)						
Basic	2.06	3.05	2.49	7.85	7.25	9.03
Diluted	2.06	3.05	2.49	7.85	7.25	9.03


Strategy

Export oriented




- Shifting focus from domestic to export markets such as Africa, Latin America, CIS* and South East Asia

Portfolio realignment



- Focus on high margin formulations such as oncology, anti-malarial and anti-diabetic products (lifestyle diseases)

Capacity expansion



- Construction of new oncology plant (Haridwar) and upgradation of existing plant (Bhiwadi) including R&D centres

Note: *Commonwealth of Independent States



Medicamen Biotech Limited

Registered Office:

1506, Chiranjiv Tower, 43 Nehru Place, New Delhi- 110019

Phone: 011-47589500 (30 Lines)

Fax: 011-26213081

E-mail: cs@medicamen.com

Website: www.medicamen.com



Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, our ability to obtain regulatory approvals, technological changes, cash flow projections, our exposure to market risks as well as other risks. Medicamen Biotech Limited does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.